ERBB2 and breast carcinoma: The cancers were classified into five classes according to surrogate subtype, including triple-negative, 33 (9.17%); human epidermal growth factor receptor 2 (HER2)-positive, 26 (7.22%); luminal A-like, 109 (30.28%); luminal B-like HER2-negative, 144 (40.0%); and luminal B-like HER2-positive, 48 (13.33%), breast cancers.